APA (7th ed.) Citation

Singh, S., Capdevila, J., Halfdanarson, T., Halperin, D., Herrmann, K., Pavel, M., . . . Kunz, P. (2025). 1735TiP NETTER-3: A phase III study of [177Lu]Lu-DOTA-TATE in patients with newly diagnosed, grade 1 and grade 2 (Ki-67<10%) advanced gastroenteropancreatic neuroendocrine tumors and high disease burden. Annals of Oncology, 36, S1020. https://doi.org/10.1016/j.annonc.2025.08.2363

Chicago Style (17th ed.) Citation

Singh, S., J. Capdevila, T.R Halfdanarson, D. Halperin, K. Herrmann, M.E Pavel, J. Xu, D. Pathak, and P.L Kunz. "1735TiP NETTER-3: A Phase III Study of [177Lu]Lu-DOTA-TATE in Patients with Newly Diagnosed, Grade 1 and Grade 2 (Ki-67<10%) Advanced Gastroenteropancreatic Neuroendocrine Tumors and High Disease Burden." Annals of Oncology 36 (2025): S1020. https://doi.org/10.1016/j.annonc.2025.08.2363.

MLA (9th ed.) Citation

Singh, S., et al. "1735TiP NETTER-3: A Phase III Study of [177Lu]Lu-DOTA-TATE in Patients with Newly Diagnosed, Grade 1 and Grade 2 (Ki-67<10%) Advanced Gastroenteropancreatic Neuroendocrine Tumors and High Disease Burden." Annals of Oncology, vol. 36, 2025, p. S1020, https://doi.org/10.1016/j.annonc.2025.08.2363.